Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in VSports app下载. gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

Comparative Study
. 2015 Oct;8(7):393-403.
doi: 10.1007/s12265-015-9643-3. Epub 2015 Sep 17.

Autologous Mesenchymal Stem Cells Show More Benefit on Systolic Function Compared to Bone Marrow Mononuclear Cells in a Porcine Model of Chronic Myocardial Infarction

T I G van der Spoel  1 , W A Gathier  1 , S Koudstaal  1 , F van Slochteren  1 , S Jansen Of Lorkeers  1 , J P G Sluijter  1   2 , I E Hoefer  3 , P Steendijk  4 , M J M Cramer  1 , P A Doevendans  1   2 , E van Belle  1 , S A J Chamuleau  5
Affiliations
Comparative Study

Autologous Mesenchymal Stem Cells Show More Benefit on Systolic Function Compared to Bone Marrow Mononuclear Cells in a Porcine Model of Chronic Myocardial Infarction

T I G van der Spoel et al. J Cardiovasc Transl Res. 2015 Oct.

VSports最新版本 - Abstract

Cardiac cell therapy is a strategy to treat patients with chronic myocardial infarction (MI). No consensus exists regarding the optimal cell type. First, a comparison between autologous bone marrow-derived mononuclear cells (BMMNC) and mesenchymal stem cells (MSC) on therapeutic efficacy after MI was performed. Next, the effect of repetitive, NOGA-guided transendocardial injection was determined via a crossover design. Nineteen pigs were allocated in three groups: (1) placebo (at 4 and 8 weeks), (2) MSC (followed by placebo at 8 weeks), or (3) BMMNC (followed by MSC at 8 weeks) delivery including a priming strategy to enhance MSC effect. At 4 weeks, ejection fraction (EF) was significantly improved after MSC injection and not by BMMNC injection VSports手机版. After 8 weeks, no difference was observed in EF between cell-treated groups demonstrating the positive systolic effect of MSC. This study showed that MSC rather than BMMNC injection improves systolic function in chronic MI. .

Keywords: Ischemic cardiomyopathy; Mesenchymal stem cell; Stem cells; Systolic function V体育安卓版. .

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Study design. BMMNC bone marrow mononuclear cells, Echo echocardiography, MI myocardial infarction, MSC mesenchymal stem cells, PV loop pressure-volume loop
Fig. 2
Fig. 2
Effects at 4 weeks after cell therapy: group 2 (MSC injection) improves systolic function compared to group 3 (BMMNC) and group 1 (placebo). Percentage of change in LVEF between baseline and 4 weeks after injection in each treatment group. *P < 0.01 compared to group 1. †P = 0.028 compared to group 3. LVEF left ventricular ejection fraction§
Fig. 3
Fig. 3
Effect at 8 weeks after (repeated) cell therapy: no difference on EF between single (group 2) versus pretreated injections (group 3) with MSC. No significant effect on ∆LVEF (baseline and 8 weeks after injection) between single and repeated cell injection was observed. LVEF left ventricular ejection fraction
Fig. 4
Fig. 4
Microcirculatory remodeling in the damaged myocardium after cell delivery 12 weeks post-MI. Microvascular formation determined by Lectin staining at sacrifice was significantly higher in the infarcted zone in group 3 (BMMNC + MSC injection) compared to the other groups (P < 0.01). Furthermore, a nonsignificant increase in vessel density was observed in both cell-treated groups in both the remote and border zones (both P > 0.1). Group 1: 4 animals, 13 images used for analysis of remote zone, 14 for border zone, 13 for infarct zone. Group 2: 5 animals, 14 images used for analysis of border zone, 23 images for border zone, 18 for infarct zone. Group 3: 6 animals, 23 images used for analysis of remote zone, 27 for border zone, 30 for infarct zone
Fig. 5
Fig. 5
Representative images of Lectin staining at sacrifice from remote area, border zone, and infarcted tissue. a Group 1 (placebo + placebo) remote, b group 1 border, c group 1 infarct. d Group 2 (MSC + placebo) remote, e group 2 border, f group 2 infarct. g Group 3 (BMMNC + MSC) remote, h group 3 border, i group 3 infarct. Magnification ×20
Fig. 6
Fig. 6
Collagen density after cell therapy. Collagen quantification 12 weeks post infarction of remote areas, border areas, and infarcted areas. A significantly decreased collagen density was observed in the infarcted zone in group 3 (BMMNC + MSC) compared to group 1 (placebo + placebo) (P < 0.01). However, in the border zone of group 3, an increase in interstitial fibrosis was measured compared to group 2 (MSC + placebo) (P < 0.05). Group 1: 4 animals, 20 images used for analysis per section. Group 2: 5 animals, 25 images used for analysis per section. Group 3: 6 animals, 30 images used for analysis per section. Note differences in Y-axis
Fig. 7
Fig. 7
Representative images of picrosirius red staining at sacrifice from remote area, border zone, and infarcted tissue. a Group 1 (placebo + placebo) remote, b group 1 border, c group 1 infarct, d group 2 (MSC + placebo) remote, e group 2 border, f group 2 infarct, g group 3 (BMMNC + MSC) remote, h group 3 border, i group 3 infarct. Magnification ×20
See this image and copyright information in PMC

References

    1. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25–e146. doi: 10.1161/CIRCULATIONAHA.107.187998. - DOI - PubMed
    1. Abdel-Latif A, Bolli R, Tleyjeh IM, et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Archives of Internal Medicine. 2007;167:989–997. doi: 10.1001/archinte.167.10.989. - DOI - PubMed
    1. van der Spoel TIG, of Lorkeers SJ, Agostoni P, et al. Human relevance of pre-clinical studies in stem cell therapy; systematic review and meta-analysis of large animal models of ischemic heart disease. Cardiovascular Research. 2011;91:649–658. doi: 10.1093/cvr/cvr113. - DOI (VSports注册入口) - PubMed
    1. Jeevanantham V, Butler M, Saad A, Abdel-Latif A, Zuba-Surma EK, Dawn B. Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters/clinical perspective. Circulation. 2012;126:551–568. doi: 10.1161/CIRCULATIONAHA.111.086074. - DOI - PMC - PubMed
    1. van Ramshorst J, Bax JJ, Beeres SL, et al. Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial. JAMA. 2009;301:1997–2004. doi: 10.1001/jama.2009.685. - DOI (V体育ios版) - PubMed

Publication types

MeSH terms